Drug Transporter (DT) Information

General Information of DT
DT ID DTD0051
Gene Name ABCB5
Protein Name ATP-binding cassette sub-family B member 5
Gene ID
340273
UniProt ID
Q2M3G0
TCDB ID
3.A.1.201.13
3D Structure

Modelled DT Structure

Method: homology modeling

Template PDB: 6QEX_A

Identity: 55.788%

Minimized Score: -2936.873 kcal/mol

Detail: Structure Info

Synonyms ABCB5; ABCB5 P-gp; ABCB5alpha; ABCB5beta; EST422562; P-glycoprotein ABCB5
DT Family ATP-Binding Cassette (ABC) Superfamily
Multidrug Resistance Exporter (MDR) Family (ABCB)
Tissue Specificity Expressed by CD133-expressing progenitor cellsamong epidermal melanocytes (at protein level). Widely expressedwith specific expression in pigment cells. Highly expressed inseveral malignant tissues: highly expressed in clinical melanomas,with low expression in normal skin. In melanoma, marks malignantmelanoma-initiating cells (MMIC), in which clinical virulenceresides as a consequence of unlimited self-renewal capacity,resulting in inexorable tumor progression and metastasis. Alsohighly expressed in a number of leukemia cells. Expressed in basallimbal epithelium.
Function This drug efflux transporter present in a number of stem cells that acts as a regulator of cellular differentiation. Able to mediate efflux from cells of the rhodamine dye and of the therapeutic drug doxorubicin.
Disease(s) Non-small cell lung cancer [ICD-11: 2C25]
Rheumatoid arthritis [ICD-11: FA20]
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(α) Mutation-induced Structural Variation
Mutation-induced Structural Variation (MSV)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

(δ) Xenobiotics-regulated Structural Variability
Xenobiotics-regulated Structural Variability (XSV)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:            3 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Brigatinib
 Approved Drug Info Non-small cell lung cancer 2C25 [1]
Doxorubicin
 Approved Drug Info Leukemia 2A60-2B33 [2]
Fostamatinib
 Approved Drug Info Rheumatoid arthritis FA20 [3]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            4 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
Glycerophosphocholine
657272
EM Info Identified using ABCB5 knockdown G3361 melanoma cells [4]
Glycerophosphoethanolamine
123874
EM Info Identified using ABCB5 knockdown G3361 melanoma cells [4]
Phospholipid degradation product unspecific N.A. EM Info Identified using ABCB5 knockdown G3361 melanoma cells [4]
Water-soluble metabolite unspecific N.A. EM Info Identified using ABCB5 knockdown G3361 melanoma cells [4]
References
1 NDA/BLA Multidisciplinary Review and Evaluation of ALUNBRIG (brigatinib) From FDA.
2 ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005 May 15;65(10):4320-33.
3 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB12010)
4 Expression of Cell-Surface Marker ABCB5 Causes Characteristic Modifications of Glucose, Amino Acid and Phospholipid Metabolism in the G3361 Melanoma-Initiating Cell Line. PLoS One. 2016 Aug 25;11(8):e0161803.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.